Analysts Issue Forecasts for Dare Bioscience Q2 Earnings

Dare Bioscience, Inc. (NASDAQ:DARE) – Research analysts at HC Wainwright issued their Q2 2026 earnings per share (EPS) estimates for shares of Dare Bioscience in a note issued to investors on Friday, May 15th. HC Wainwright analyst D. Tsao anticipates that the biotechnology company will post earnings of ($0.25) per share for the quarter. The consensus estimate for Dare Bioscience’s current full-year earnings is ($1.50) per share. HC Wainwright also issued estimates for Dare Bioscience’s Q3 2026 earnings at $0.09 EPS, Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($0.57) EPS, FY2027 earnings at ($0.45) EPS, FY2028 earnings at $0.01 EPS and FY2029 earnings at $1.17 EPS.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Dare Bioscience in a research note on Monday, April 20th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Dare Bioscience has a consensus rating of “Hold” and an average target price of $10.00.

Dare Bioscience Stock Down 2.8%

Dare Bioscience stock opened at $2.11 on Tuesday. The business has a 50-day simple moving average of $2.00 and a two-hundred day simple moving average of $1.92. The company has a market cap of $31.61 million, a P/E ratio of -2.22 and a beta of 1.09. Dare Bioscience has a 52-week low of $1.27 and a 52-week high of $9.19.

Dare Bioscience (NASDAQ:DARE) last released its quarterly earnings results on Thursday, May 14th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.13. The firm had revenue of $0.15 million for the quarter, compared to the consensus estimate of $0.03 million.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in DARE. Virtu Financial LLC bought a new position in shares of Dare Bioscience during the 3rd quarter valued at approximately $37,000. LPL Financial LLC bought a new position in shares of Dare Bioscience during the 4th quarter valued at approximately $28,000. Finally, Raymond James Financial Inc. grew its stake in shares of Dare Bioscience by 810.6% during the 3rd quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 13,650 shares during the period. 6.70% of the stock is currently owned by institutional investors.

Dare Bioscience News Roundup

Here are the key news stories impacting Dare Bioscience this week:

• Positive Sentiment: Brookline Capital Markets raised its FY2026 EPS estimate for Dare Bioscience, suggesting slightly improved near-term expectations for the women’s health biotech. DARE stock page
• Positive Sentiment: HC Wainwright’s long-range outlook was constructive, with estimates showing a path to profitability in later years, including positive EPS projected for FY2028 and FY2029. DARE stock page
• Neutral Sentiment: The company announced it has started a Phase 2 study of DARE-HPV, a treatment for persistent high-risk HPV infection, backed by a $10 million ARPA-H-funded contract. The trial is an important pipeline update, but topline data is not expected until 2027, so the near-term stock impact is likely limited. Article: Daré Bioscience Initiates Phase 2 Study of DARE-HPV
• Negative Sentiment: Several analyst updates still point to expected losses in 2026 and 2027, reinforcing that Dare Bioscience remains far from consistent profitability. DARE stock page

Dare Bioscience Company Profile

Dare Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery.